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Abstract
There are limited data on the pharmacokinetics of generic nucleoside reverse transcriptase inhibitors
(NRTIs) in native African populations, where they are commonly used. We characterized the
pharmacokinetics of lamivudine (n=27), zidovudine (n=16) and stavudine (n=11) in HIV/TB co-
infected Ghanaians, and evaluated associations between zidovudine metabolism and UDP-
glucuronosyltransferase (UGT) 2B7 polymorphisms. Lamivudine, zidovudine, and stavudine
apparent oral clearance (CL/F) values [mean±SD (CV%)] were 7.3±2.8 (39%), 31.9±33.6 (106%),
and 16.4±5.8 (35%) mL/min/kg, respectively, whereas half-life values were 4.2±1.9 (46%), 8.1±7.9
(98%), and 1.5±1.0 (65%) hr, respectively. Zidovudine CL/F was 196% higher (P=0.004) in
UGT2B7*1c (c.735A>G) carriers versus non-carriers. This was confirmed using human liver bank
samples (n=52), which showed 48% higher (P=0.020) zidovudine glucuronidation and 33% higher
(P=0.015) UGT2B7 protein in UGT2B7*1c carriers versus non-carriers. In conclusion, generic NRTI
pharmacokinetics in HIV/TB co-infected Ghanaians are similar to other populations, while the
UGT2B7*1c polymorphism may explain in part relatively high interindividual variability in
zidovudine clearance.
Keywords
NRTIs; pharmacokinetics; UGT2B7; rifampin; interindividual variability
INTRODUCTION
Antiretroviral combination regimens of dual nucleoside/nucleotide reverse transcriptase
inhibitors (NRTIs) plus either a protease inhibitor (PI) or a non-nucleoside reverse transcriptase
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inhibitor (NNRTI) are preferentially used in treatment-naïve human immunodeficiency virus
(HIV) infected patients to achieve maximum durable anti-viral activity.1, 2 The dual-NTRI
backbone drugs differ substantially in pharmacokinetic properties, potency and durability of
virologic suppression, incidence and type of short-and long-term toxicities, propensity to select
for resistance mutations, dosing convenience and drug-drug interaction potential.1 The newer
once-daily fixed-dose combinations of tenofovir/emtricitabine or lamivudine/abacavir are the
preferred choices in industrialized countries because of dosing convenience and lower
incidence of short-and long-term toxicities.1, 2 However, in resource poor settings, low cost
generic forms of lamivudine in combination with zidovudine or co-administered with stavudine
are the predominant dual-NRTI backbone.3
The pharmacokinetics of the antiretroviral drugs may depend on genetic polymorphisms of
drug metabolizing enzymes or transporters, biological factors (such as age, gender, body
weight, or disease state), drug-drug interactions and/or drug formulation.4–7 While the
pharmacokinetics of the NRTIs have been well established for the brand formulations in HIV-
infected populations in industrialized countries,7–10 there is limited data on the
pharmacokinetics of the generic equivalents in African populations. The pharmacokinetics of
generic tablets of the fixed-dose combination of lamivudine/stavudine/nevirapine and brand-
name separate formulations of lamivudine, stavudine and nevirapine have been evaluated in
HIV-infected patients in sub-Saharan Africa.11, 12 Although plasma levels of lamivudine were
found to be similar for the generic and brand-name formulations in those studies, one of the
studies,11 found lower stavudine concentrations, and the other study12 found higher stavudine
peak concentrations for generic compared with non-generic formulations.
In HIV-infected patients with TB coinfection who require rifampin-containing therapy, the
World Health Organization recommends efavirenz with lamivudine/zidovudine or lamivudine/
stavudine as the first-line antiretroviral regimen.3 While the pharmacokinetics of efavirenz has
been studied in this population because of the concern of drug-drug interactions,13, 14 to our
knowledge, there are no pharmacokinetic data for the generic NRTIs components in HIV/TB
co-infected individuals on TB therapy. Apart from possible impairment of drug absorption
resulting from the effects of advanced HIV disease and TB infection,15, 16 co-administered
rifampin has the propensity to enhance drug clearance mechanisms involving cytochrome
P450, uridine diphosphate (UDP)-glucuronosyltransferase (UGT), and drug transporters which
may result in detrimental drug-drug interactions.17 Rifampin co-administration was previously
associated with an average of 47 – 50% reduction in zidovudine area under the curve in
asymptomatic HIV-infected patients.5, 6 Significant rifampin-induced drug-drug interactions
are not expected with the other NRTIs as these drugs are not metabolized by hepatic CYP
enzymes and are not considered substrates of the rifampin-inducible P-glycoprotein
transporter. Zidovudine and lamivudine are known to be substrates for the efflux transporter
multidrug resistance protein 4 (MRP4), and over expression of this transporter is associated
with impaired intracellular accumulation of the monophosphates.18 However, in one small
study, rifampin did not appear to have any significant effect on the expression of MRP4.19
Zidovudine undergoes extensive first-pass extraction and is eliminated primarily through
hepatic glucuronidation by UGT2B7.20 The large interindividual variation in zidovudine
kinetics as well as the variability in the ability to glucuronidate zidovudine would indicate that
there may be functional polymorphisms of UGT2B7 that affect zidovudine disposition.21, 22
Although several polymorphisms in the UGT2B7 gene have been identified that could
potentially impact zidovudine pharmacokinetics,23, 24 as far as we are aware this hypothesis
has not been evaluated as yet.
In this study, we determined the pharmacokinetics of lamivudine, zidovudine and stavudine in
a cohort of 27 HIV/TB co-infected Ghanaian patients receiving generic preparations of either
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lamivudine/zidovudine (fixed dose combination) or lamivudine and stavudine during
concurrent rifampin-containing TB therapy. In addition to comparing our results to published
data for sub-Saharan black African HIV-infected patients who were not receiving rifampin-
containing TB therapy, we compared lamivudine pharmacokinetics between drug
formulations. We also evaluated the association between two common UGT2B7
polymorphisms (c.735A>G, a marker for the UGT2B7*1c allele and c.802C>T, a marker for
the UGT2B7*2 allele) and zidovudine pharmacokinetics in the 16 patients that received this
drug. These pharmacogenetic results were replicated using a retrospective analysis of large
bank of human livers that were phenotyped for zidovudine glucuronidation activity as well as
UGT2B7 protein and mRNA content.
METHODS
Study patients
HIV/TB co-infected patients aged 18 years or older, with CD4 cell count ≤ 250 cells/µl on TB
therapy were enrolled. The anti-tuberculosis regimen consisted of isoniazid 5 mg/kg (max, 300
mg), rifampin 10 mg/kg (max 600 mg), pyrazinamide 25 mg/kg (max 2 gm) and ethambutol
15 mg/kg (max 2 gm) daily. All patients were also on trimethoprim-sulfamethoxazole at the
time of initiating HAART and at the time of pharmacokinetic sampling. Antiretroviral therapy
consisted of efavirenz 600 mg daily plus lamivudine 150 mg and zidovudine 300 mg (duovir®,
Cipla, Goa, India) twice daily, or lamivudine 150 mg (Strides Arcolab, Bangalore, India) and
stavudine 40 mg (Strides Arcolab, Bangalore, India) twice a daily. For patients with body
weight < 50 kilograms, stavudine dose was 30 mg daily. The median duration of TB therapy
to initiation of HAART was 35 (range, 14 – 70) days. Patients were instructed to switch their
evening efavirenz administration to mornings three days prior to admission to the hospital for
sampling. On the day of pharmacokinetic testing, all drugs including efavirenz were co-
administered in the morning. The Institutional Review Boards of the University of Ghana
Medical School, and The Miriam Hospital approved the study. A signed consent was obtained
from all patients prior to enrolment.
Clinical monitoring and pharmacokinetic sampling
Study participants were evaluated at study entry and baseline liver function tests, CD4 cell
count and HIV RNA were done prior to starting HAART. No patients discontinued study
medications due to clinical or laboratory toxicity and one patient died prior to pharmacokinetic
testing. To determine the steady-state pharmacokinetics of the antiretroviral drugs in a
rifampin-induced sate, sampling for drug concentrations were performed on day 14 of
concurrent HIV and TB therapy. Blood samples were obtained at times 0, 0.5, 1, 1.5, 2, 3, 4,
6, 8, and 12 hours after observed administration of anti-tuberculous and antiretroviral drugs.
Seven to 10 milliliters of blood were collected in heparinized plastic tubes, and centrifuged at
3000 g for 10 minutes. Plasma was separated, transferred into labeled 1.2 mL cryovials, and
frozen at –70°C until shipping to the United States. The frozen plasma samples were shipped
on dry ice for analysis and were received in good condition. Plasma samples were stored at
−70°C until drug concentration assay.
Analytical and pharmacokinetic analysis
Drug concentrations in blood plasma were measured simultaneously using a validated high-
performance liquid chromatography (HPLC)/UV method.25 The method was validated over
the range of 10–10,000 ng/ml for all three analytes. Assay accuracy estimates determined at
three different concentrations ranged from 97.2 to 105%, while within- and between-day
precision measures ranged from 0.5 to 5.1% and 0.5 to 5.6%, respectively. Pharmacokinetic
parameters, including the area under the concentration-time curve for the dose interval
(AUC0–12h), were estimated using WinNonlin (version 5.2, Pharsight, Inc. Mountain View,
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California, USA). For drug concentration measurements below the lower limit of detection at
12 hours, AUC was computed from time 0 − the last time that drug concentration was
measurable (0−Tlast). For these computations, concentration measurements below the lower
limit of detection were imputed as zero and those below the lower limit of quantitation (LLQ)
were imputed as 50% LLQ. Weighting was applied during HPLC/UV analysis of samples, but
no weighting was used for the noncompartmental pharmacokinetic analysis. Drug
concentration measurements were performed at the University of North Carolina Center for
AIDS Research (CFAR) Clinical Pharmacology and Analytical Chemistry Core, which is
CLIA certified, and participates in quarterly national and international external proficiency
testing.
Zidovudine glucuronidation, UGT2B7 protein and mRNA content
Demographic details of the 52 human liver bank samples used to prepare matched microsomes,
DNA and RNA have been published previously.26 Briefly, donors included 48 men and 14
women, and were primarily white American, but also included 3 African-Americans and 2
Hispanics. Mean (±SD) donor age was 40 (±20) years. The human liver microsome (HLM)
zidovudine glucuronidation activities and UGT2B7 protein content measurements used for
analysis here have been reported in detail previously23, while UGT2B7 and GAPDH mRNA
contents have not been reported previously. Enzyme activities were expressed as nanomoles
per minute per milligram of microsomal protein, while UGT2B7 specific protein content
measured by immunoblotting was expressed relative to the liver with the lowest UGT2B7
content. Total RNA was also extracted from these same liver samples with Trizol reagent
(Invitrogen) and used to measure UGT2B7 and GAPDH mRNA content with a branched DNA
signal amplification assay. Capture well plates were from Bayer Diagnostics (QuantiGene,
Bayer Diagnostics, East Walpole, Massachusetts, USA), while UGT2B7 and GAPDH specific
probe sets were from XenoTech LLC (Kansa City, Kansas, USA). The assay technique was
similar to that we have previously described for CYP2B6 mRNA content quantification.26
Luminescence from the capture wells was measured using a luminescence counter (Wallace
Trilux, #1450 Microbeta, PerkinElmer Life Sciences, Boston, Massachusetts, USA). UGT2B7
mRNA data were normalized to GAPDH data and expressed relative to the liver with the lowest
value. Determinations were made in quadruplicate on 4 separate days and results averaged.
Inter-assay variability averaged 29% (Spearman correlation coefficient = 0.91).
UGT2B7 genotyping
Genomic DNA was isolated from blood spots collected from patients onto Whatman FTA
Classic Cards (Whatman International Ltd, Kent, United Kingdom) according to the
manufacturer’s protocol. Genomic DNA was also isolated from the human liver bank tissues
using DNAzol reagent and stored at − 80°C until use. Genotypes for the UGT2B7 exon 2 SNPs
c.802C>T (H268Y; UGT2B7*2; rs7439366) and c.735A>G (UGT2B7*1c; rs28365062) were
determined by genomic PCR amplification and direct sequencing of exon 2 as we have
previously described with minor modifications.23 Primers included forward PRI-122, 5´-TTA
TGA TTA TGA GCA TAC TGA TGC-3´ and reverse PRI-123, 5´-TAC TTG CAC ATA TTC
TAT CTT TTG-3´. The PCR method (GeneAmp9600, Applied Biosystems, FosterCity, CA)
used an initial denaturation at 94°C for 4min, then 40 cycles of 94°C for30s, 62°C for 30s, and
72°C for 30s, followed by 72°C for 15min. The 829-bp PCR product was treated with ExoSapit
(USB Corporation, Cleveland, OH) and cycle sequenced (ABI Prism 3100, Applied
Biosystems) using PRI-123. UGT2B7*1a, UGT2B7*2, and UGT2B7*1c alleles (according to
the UGT Allele Nomenclature Committee recommendation http://www.ugtalleles.ulaval.ca)
were inferred from the SNP genotype data.
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All analytic statistical analyses were performed using Sigmaplot 11 software (Systat, San Jose,
CA). This software automatically assesses data for normality of distribution and equal variance
to ensure appropriateness of parametric statistical testing methods, and if necessary,
nonparametric tests are used instead. All data were summarized as mean and standard deviation
(SD). Univariate analyses of effects of patient demographics on mean CL/F of each drug were
assessed by unpaired t-test (gender, and alcohol use) or by linear regression (for age, body
weight and body mass index, baseline CD4 cell count and HIV RNA level). A backward
stepwise regression analysis containing the above patient factors was performed to identify
independent variables associated with CL/F of each drug. Possible effects of UGT2B7 allele
carrier status on patient pharmacokinetic parameters and human liver zidovudine
glucuronidation rate, UGT2B7 protein and mRNA content were evaluated using Student’s
unpaired t-test or by Mann-Whitney rank sum test (if data showed non-normal distribution and/
or unequal group variance). The effect of UGT2B7 diplotype on zidovudine glucuronidation
activities was assessed by ANOVA with post-hoc pair-wise multiple comparisons by Student-
Newman-Kuels test. A P value of less than 0.05 was considered significant. Genotype
frequencies were tested for consistency with expected Hardy-Weinberg equilibrium by Chi-
squared test. Differences in allele frequencies between patient and liver bank samples were
also assessed by Chi-squared test.
RESULTS
Patient characteristics
Twenty-seven HIV/TB co-infected Ghanaian patients were studied. All patients were black,
had a mean (± SD) CD4 cell count of 101 (± 80) cells/µL, and included 20 males and 7 females.
The mean (± SD) age was 40.2 (± 7.6) years, body weight was 56.1 (± 9.7) kg and body mass
index (BMI) was 19.0 (± 3.1) kg/m2.
Lamivudine, zidovudine and stavudine pharmacokinetics
The mean steady-state plasma drug concentration-time profiles of each drug for all patients
are shown in Figure 1. Derived pharmacokinetic parameters are given in Table 1. All drugs
were rapidly absorbed with a mean Cmax achieved between 1 and 3 hours of administration
(Figure 1). Lamivudine and zidovudine plasma concentrations were quantifiable (> 10 ng/ mL)
in most patients prior to dosing and at 12 hour post-dosing (Figures 1). In contrast, stavudine
plasma concentrations were below the limit of quantitation for all patients prior to dosing and
but one patient at 12 hour post-dosing.
The coefficients of variation for zidovudine pharmacokinetic parameters were consistently
higher by as much as 2-fold compared with lamivudine and stavudine pharmacokinetic
parameters (Table 1). The greatest difference was observed for body weight normalized CL/F
values with a CV of 106% for zidovudine compared with 39% and 35% for lamivudine and
stavudine, respectively.
Average lamivudine concentrations were consistently higher in patients who received
lamivudine with stavudine as separate preparations as compared to those who received the
fixed-dose co-formulated lamivudine/zidovudine tablets at each timed point (data not shown).
This difference was reflected by mean lamivudine AUC and Cmax values, which were 26%
(P=0.031, unpaired t-test), and 41% (P=0.025, unpaired t-test) higher, respectively in those
patients that received lamivudine with stavudine compared to the lamivudine/zidovudine
preparation. Although mean body weight normalized CL/F was 12% lower in the patients that
received lamivudine with stavudine, this difference did not achieved statistical significance
(P>0.05, unpaired t-test). Lamivudine Tmax and half-life were also not different between these
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preparations (P>0.05, unpaired t-test). However, there were significant differences in mean
body weight (49.7 vs. 60.5 kg, P = 0.003, unpaired t-test), and BMI (16.9 vs. 20.4 kg/m2, P =
0.002, unpaired t-test) between the patients that received lamivudine with stavudine compared
with the lamivudine/zidovudine preparation, respectively.
Possible effects of age and body mass index (BMI) on body weight normalized CL/F of each
drug were evaluated by linear regression, while sex effects were evaluated by unpaired t-test.
Stavudine CL/F was somewhat higher in females (n=3) than in males (n=8) with mean (± SD)
values of 23.0 ± 6.7 and 14.0 ± 3.1 mL/min/kg, respectively (P = 0.014, unpaired t-test).
Lamivudine CL/F normalized for body weight appeared to decline modestly with increasing
age of the patients in both univariate and multivariate analysis (P = 0.021) (Figure 2). Sex did
not appear to influence the clearance of lamivudine or zidovudine (P>0.05, unpaired t-test),
and BMI was not associated with clearance of any of the drugs evaluated (R2 < 0.30, P>0.05,
linear regression).
Effect of UGT2B7 polymorphisms on zidovudine pharmacokinetics and metabolism
The UGT2B7 exon 2 SNPs c.802C>T and c.735A>G were genotyped in the 16 patients from
the pharmacokinetic study who had received zidovudine, and also in 52 of the liver bank
samples that we had previously assayed for zidovudine glucuronidation activity, UGT2B7
protein and mRNA content.23, 24 Derived genotype frequencies of the UGT2B7 exon 2 SNPs
c.802CC, CT and TT genotype were 62.5% (n = 10), 31.3% (n = 5) and 6.3% (n = 1),
respectively in the 16 HIV/TB co-infected Ghanaian patients and 23.1% (n = 12), 42.3% (n =
22) and 34.6% (n = 18) respectively among the 52 liver samples. The genotype frequencies of
the UGT2B7 exon 2 SNPs c.735AA, AG, GG were 50.0% (n= 8), 37.5% (n = 6) and 12.5% (n
= 2), respectively in the HIV/TB co-infected Ghanaian patients and 76.9% (n = 40), 21.2% (n
= 11) and 1.9% (n = 1) respectively among the liver samples. The distributions of SNP
genotypes were consistent with those predicted by the Hardy-Weinberg equilibrium for both
patient and liver samples (P > 0.05).
In addition to c.802C>T being nonsynonymous (H268Y), both SNPs were chosen for this
analysis because they allowed discrimination of the 3 most common UGT2B7 alleles that have
been identified to date.27, 28 Alleles were inferred for each patient and liver sample based on
the SNP genotypes, and were either UGT2B7*2 (c.802C>T), UGT2B7*1c (c.735A>G) or
UGT2B7*1a (i.e. reference sequence by exclusion). These allele designations had been
approved previously by the UGT Allele Nomenclature Committee (available at
http://www.ugtalleles.ulaval.ca).
UGT2B7 allele frequencies differed somewhat between the Ghanaian patients and the
(primarily white American) liver bank samples. The frequency of UGT2B7*2 in the Ghanaian
patients (0.19) was about half that of the human liver bank samples (0.38) (Χ2 = 9.9; P = 0.002).
In contrast, the frequency of UGT2B7*1c in the Ghanaian patients (0.25) was over double that
of the human liver bank samples (0.12) (Χ2 = 5.6; P = 0.017). However, the frequency of the
reference allele UGT2B7*1a was similar in the Ghanaian patients (0.55) compared with the
human liver bank samples (0.50) (Χ2 = 1.8; P = 0.18).
We next evaluated the possible effects of these UGT2B7 alleles on zidovudine
pharmacokinetics. As shown in Table 2, carriers of either UGT2B7*1a or UGT2B7*2 did not
have significant differences as compared with non-carriers for any of the zidovudine
pharmacokinetic parameters evaluated. However, carriers of UGT2B7*1c appeared to have
higher zidovudine concentrations at each sampling point (Figure 3A). The carriers of
UGT2B7*1c had 57% lower mean AUC (P = 0.029, unpaired t-test), 196% higher mean CL/
F (P = 0.004, unpaired t-test) (Figure 3B), and 67% shorter mean elimination half-life (P =
0.030, unpaired t-test) compared with non-carriers.
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We then sought to confirm these findings using the human liver bank samples. As shown in
Table 3 and Figure 4, UGT2B7*1c carriers showed 48% higher mean zidovudine
glucuronidation activity (P = 0.020, unpaired t-test) and 33% higher mean microsomal
UGT2B7 protein content (P = 0.015, unpaired t-test) compared with non-carriers. These effects
of UGT2B7*1c on zidovudine glucuronidation and UGT2B7 protein were also observed when
the 3 livers from non-white donors were excluded from the analysis (data not shown). Although
mean UGT2B7 mRNA content was somewhat lower in UGT2B7*1c carriers compared non-
carriers, this difference was not statistically significant (P > 0.05, unpaired t-test). Neither
UGT2B7*1a nor UGT2B7*2 carriers were associated with altered zidovudine glucuronidation
activity, microsomal UGT2B7 protein content or UGT2B7 mRNA content (P>0.05, unpaired
t-test) (Table 3).
Finally, we explored the possible effect of UGT2B7 diplotype on zidovudine glucuronidation,
UGT2B7 protein and UGT2B7 mRNA content to determine whether particular diplotypes
(rather than simple variant carrier status) might explain the observed liver phenotype. As shown
in figure 5, although the ANOVA indicated significant effects of diplotype on zidovudine
glucuronidation activity (P = 0.045), with higher mean activities in UGT2B7*1c carriers, post-
hoc pairwise comparisons by Student-Newman Kuels method did not identify individual
groups that were significantly different from each other. Importantly, no differences were
observed between UGT2B7*1a/*1a, *1a/*2, and *2/*2 groups suggesting that the *2 allele is
not likely to have effects on activity independent of any *1c allele effect. Similar analyses of
effects on diplotype on UGT2B7 protein and mRNA content by ANOVA were not significant
(P > 0.05, data not shown)
DISCUSSION
In this study, we determined the pharmacokinetic parameters of three commonly used generic
NRTIs in HIV/TB co-infected patients who were also receiving 4-drug anti-tuberculosis
therapy in resource-limited settings. To our knowledge, this is the first study to describe the
steady-state pharmacokinetic profiles of generic lamivudine, zidovudine and stavudine in
patients with TB/HIV coinfection on concurrent therapy. Our study is also the first to identify
a significant pharmacogenetic relationship between a common UGT2B7 allele and zidovudine
clearance in human patients and also zidovudine glucuronidation in human liver.
To date, published studies of the pharmacokinetics of generic antiretroviral agents in resource-
limited settings have not included patients taking known inducers or inhibitors of cytochrome
P450 enzymes and drug transporters.11, 12, 29 Consequently, it is not known if these patients
would achieve similar bioavailability of these drugs. We found the steady-state plasma AUC
of lamivudine to be 0.98 times and 1.1 times that reported for generic and brand-name
lamivudine (respectively) in HIV-infected Ugandan patients who were given lamivudine/
stavudine/nevirapine (Triomune®, Cipla, Goa, India) and the patented versions of the drugs
(Epivir®, GlaxoSmithKline, Research Triangle Park, NC, USA; Zerit®, Bristol Myers Squibb,
Princeton, NJ, USA; Viramune®, Boehringer Ingelman, Columbus, OH, USA).11
Furthermore, the steady-state plasma AUC of stavudine was 1.5 and 1.3 times that reported
for generic and brand-name stavudine (respectively) in the above-mentioned study.11 We were
not able to identify published studies that have evaluated zidovudine pharmacokinetics in HIV-
infected black Africans. However the zidovudine AUC in our patients was 0.78 and 0.84 of
values reported for generic and brand name zidovudine (respectively) in HIV-negative Indian
women.29 These comparisons to published data suggest that lamivudine and stavudine
concentrations in the TB/HIV co-infected patients in present study were at least similar to (or
perhaps slightly higher than, in the case of stavudine) other patients that were not taking TB
medications. The 14 to 21% lower zidovudine AUC in our patients is consistent with induction
of zidovudine clearance by rifampin, though it is lower than the 47 – 50% reduction previously
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reported.5, 6 The apparent minimal effect of rifampin on zidovudine AUC in our study could
be due to population differences between our patients and the historical controls and/or the
effect of concurrent medications such as trimethoprim/sulfamethoxazole. Trimethoprim with
or without sulfamethoxazole has been shown to decrease zidovudine renal clearance,30, 31 and
could have in part minimized the induction effect of rifampin in our study population.
We observed high variability in zidovudine clearance (over 100% coefficient of variation)
relative to the clearance of stavudine and lamivudine. The mechanism underlying this high
variability of zidovudine is not well understood but may involve polymorphisms in genes
encoding proteins involved in zidovudine disposition, including UGT2B7. In previous work
using our human liver bank, we determined that the most common UGT2B7 nonsynonymous
SNP (c.802C>T, UGT2B7*2) was not associated with altered zidovudine glucuronidation or
UGT2B7 protein expression.23 These findings were independently confirmed in a more recent
study of human liver bank samples by Peterkin et al.32 UGT2B7 gene re-sequencing by several
groups have identified other polymorphisms, many of them in linkage disequilibrium within
discrete haplotype blocks.27, 28 Consequently in addition to UGT2B7*2, we also assayed for
the common SNP c.735A>G (defining the UGT2B7*1c allele) and showed higher in vivo
clearance and also faster hepatic glucuronidation of zidovudine in individuals carrying this
allele. Such similar results in two clearly distinct populations (i.e. HIV-infected Ghanaian
patients and white American liver donors) suggest that these genotype-phenotype associations
are unlikely to have occurred simply by chance. Rather, it implies that the c.735A>G SNP, or
perhaps another variant in significant linkage disequilibrium with this SNP (in both white and
black populations), may provide a mechanistic explanation for enhanced UGT2B7 gene
expression.
An important and novel finding of this study is that c.735A>G (UGT2B7*1c) was significantly
associated with higher zidovudine glucuronidation activity as well as UGT2B7 protein content
in a human liver bank, confirming the in vivo association between UGT2B7*1c and zidovudine
clearance. This association is also confirmed in part by a recent study by Innocenti et al that
showed about 45% faster 3-hydroxy-glucuronidation of morphine (another UGT2B7 substrate)
in human livers that carried the intron 1 SNP (IVS1 +985A>G).24 This latter SNP is in
significant linkage disequilibrium with c.735A>G and also the exon 4 SNP (c.1062C>T).
Although they did not measure hepatic UGT2B7 protein content, they did evaluate UGT2B7
mRNA content and splicing. Similar to our findings with zidovudine, they also found no effect
of UGT2B7*2 on morphine 3-glucuronidation or on UGT2B7 mRNA expression.24 However,
in contrast to our study, where UGT2B7 mRNA levels were unchanged, they found higher
UGT2B7 mRNA expression in carriers of the intron 1 SNP. This discrepancy may relate to the
mechanism by which these noncoding SNPs may alter gene expression through alteration of
mRNA splicing regulatory elements, as was proposed by Innocenti et al.24 Several splice
variants of UGT2B7 have been observed, and it is possible that our mRNA assay differed from
Innocenti’s assay in the splice forms quantified.24 For example, our mRNA assay may have
quantified total UGT2B7 mRNA forms including those that were aberrantly spliced and
predicted to result in truncated UGT2B7 protein.
Polymorphisms in other genes associated with zidovudine disposition such as those encoding
drug transporters have the potential to explain the variability in zidovudine clearance observed
in this study and warrant future evaluation. A trend (P=0.06) for elevated peripheral blood
mononuclear cell zidovudine triphosphate levels was observed in carriers of the ABCC4
(MRP4) c.3724G>A variant.4
The clinical relevance of the association between UGT2B7 genetic variation and zidovudine
metabolism and disposition is as yet unclear. Zidovudine like all NRTIs require intracellular
phosphorylation to form the active triphosphate moieties that exert clinical effect.33 While
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zidovudine pharmacologic variability affects treatment response,34 no relationship between
plasma zidovudine concentrations and clinic effect has been demonstrated. However, percent
change in CD4 cell count and rate of decline in HIV RNA in plasma during zidovudine-
containing therapy were related to intracellular concentrations of zidovudine triphosphate.35,
36 Furthermore, a higher total intracellular concentration of the phosphorylated moieties of
zidovudine was associated with increased probability of reduced hemoglobin levels.37 As the
relationship between zidovudine plasma exposure and intracellular triphosphate concentrations
is currently not predictable, further studies are needed to define the influence of UGT2B7*1c
carriers status on intracellular concentrations of zidovudine-triphosphate, as well as clinical
effect (efficacy and toxicity).
We also investigated potential patient factors that may influence the pharmacokinetic profile
of each of the drugs evaluated. Except for a possible small effect of sex on stavudine CL/F
normalized for body weight and age on lamivudine CL/F normalized for body weight, patient
demographics did not appear to influence drug exposure in our population. However, these
results should be interpreted with caution, as the study was not powered sufficiently to detect
relatively small differences. The effect of sex on stavudine clearance is not known as few
studies have explored the influence of sex on the disposition of antiretrovirals,38 and the largest
and most comprehensive previous pharmacokinetic study of 81 patients included only 7
women.8 The observed influence of age on lamivudine CL/F needs to be validated in a larger
population. Though, it has been shown that children younger than 12 years old tend to have
higher values for lamivudine CL/F than children aged 12 – 18 years old, age has not been
shown to influence lamivudine CL/F in adults.39
There are no known interactions between lamivudine and zidovudine or stavudine.40, 41 The
lower AUC of lamivudine observed in the patients who received the co-formulated tablets
lamivudine/zidovudine compared to the separate lamivudine tablets given with stavudine could
be due to the significant differences in body weight or BMI between the two groups. Clearance
and half-life of lamivudine did not differ between the two groups to suggest differences in
elimination of the drug.
We recognize that our study had some limitations. The size of the study population was small
and so failure to find significant relationships between pharmacokinetic parameters of some
of these drugs and patient factors such as age, sex, BMI does not exclude the existence of
significant relationships. Comparison of drug exposure in our study patients to historical
controls rather than an appropriate control that did not receive rifampin-containing TB therapy
does not allow us to_exclude the effect of population differences. The differences in lamivudine
exposure between patients who received lamivudine/zidovudine and lamivudine/stavudine
should also be interpreted with caution as it may be due to differences in disease state, as
patients who had hemoglobin < 8g/dL were preferentially given stavudine. Rifampin is known
to induce the activity of UGT2B7,5, 6 and trimethoprim has been shown to decrease renal
clearance of zidovudine by 58% during coadministration but had no influence on the ratio of
zidovudine glucuronide to zidovudine.30, 31 Although, these patients were on several
concurrent medications including rifampin and trimethoprim-sulfamethoxazole, we do not
think the concurrent medications confounded the relationship between UGT2B7
polymorphism and zidovudine metabolism as all patients received these medications at the
time of initiation of HAART and at the time of PK testing.
Despite the above limitations, this pilot study provides important pharmacokinetic data on
commonly used generic NRTIs in HIV/TB co-infected patients receiving concurrent TB
therapy, and identifies a novel association between UGT2B7 genetic variation and zidovudine
metabolism and disposition. The influence of UGT2B7*1c carriers status on intracellular
concentrations of zidovudine and it anabolites, as well as clinical effect (efficacy and toxicity)
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needs to be investigated as it may have implications for individualized therapy or dosing of
zidovudine.
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Mean steady-state plasma concentration-time profiles of lamivudine, zidovudine and stavudine
in HIV/TB co-infected patients during concurrent HIV and TB therapy. Of the 27 total patients
studied, 16 patients received the lamivudine with zidovudine (fixed dose combination) and 11
patients received lamivudine with stavudine. Error bars indicate standard error of the mean.
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Relationship between apparent oral clearance of lamivudine normalized for body weight and
the age of HIV/TB co-infected patients receiving lamivudine, with zidovudine or stavudine.
All the patients received efavirenz, 4-drug TB therapy, as well as trimethoprim-
sulfamethoxazole.
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Effect of UGT2B7*1c allele on mean (±SE) zidovudine concentration-time profile (A) and
body weight normalized apparent oral clearance (B). Differences between carrier and non-
carrier groups were evaluated by Mann-Whitney rank sum test. Horizontal bars represents
median.
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Effect of UGT2B7*1c allele on glucuronidation of zidovudine (A), relative UGT2B7 protein
content in human liver microsomes (B) and relative mRNA (C). Differences between carrier
and non-carrier groups were evaluated by unpaired t-test (protein and mRNA), or by Mann-
Whitney rank sum test (zidovudine glucuronidation).
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Effect of UGT2B7 genotype on liver zidovudine glucuronidation activity. Bars represent mean
± SD values and group differences were evaluated by ANOVA.
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Table 1
Plasma pharmacokinetic parameters for lamivudine, zidovudine, and stavudine in 27 Ghanaian HIV/TB co-infected
patients. All patients also received efavirenz and rifampin-containing TB therapy. Values represent mean ± SD
(coefficient of variation).
Parameter Lamivudine (n=27) Zidovudine (n=16) Stavudine (n=11)
Cmax (ng/mL) 1095 ± 506 (46%) 1092 ± 811 (74%) 310 ± 173 (56%)
Tmax (h) 2.3 ± 1.5 (66%) 1.6 ± 1.1 (70%) 2.6 ± 1.6 (63%)
Half life (h) 4.2 ± 1.9 (46%) 8.1 ± 7.9 (98%) 1.5 ± 1.0 (65%)
AUC (ng/mL*h) 5843 ± 2580 (44%) 3368 ± 2747 (82%) 865 ± 223 (26%)
CL/F (mL/min/kg) 7.3 ± 2.8 (40%) 31.9 ± 33.6 (106%) 16.4 ± 5.8 (35%)
Vd/F (L/kg) 2.6 ± 1.5 9.9 ± 4.7 1.7 ± 0.7
Cmax, peak concentration; Tmax, time to peak concentration; h, hour; AUC, area under curve; CL/F, apparent oral clearance normalized for body weight;
Vd/F, volume of distribution normalized for body weight.
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Table 2
Effect of UGT2B7 allele on mean ± SD zidovudine pharmacokinetic parameters measured in 16 HIV/TB co-infected
patients who were also receiving lamivudine and rifampin-containing therapy.
Parameter UGT2B7*1a non-carriers UGT2B7*1a carriers P valuea
Number of patients 5 11
Cmax (ng/mL) 830 ± 224 1310 ± 909 0.271
Tmax (h) 1.5 ± 0.6 1.6 ± 1.3 0.884
Half-life (h) 5.3 ± 7.2 9.4 ± 8.3 0.247b
AUC (ng/mL*h) 2945 ± 1739 3867 ± 3061 0.552b
CL/F (mL/min/kg) 38.3 ± 28.6 28.9 ± 36.5 0.365
Vd/F (L/kg) 8.5 ± 5.9 10.5 ± 4.2 0.453
UGT2B7*1c non-carriers UGT2B7*1c carriers
Number of patients 8 8
Cmax (ng/mL) 1302 ± 968 1018 ± 550 0.842b
Tmax (h) 1.4 ± 1.2 1.8 ± 1.1 0.274b
Half-life (h) 12.2 ± 9.0 4.0 ± 4.0 0.030b
AUC (ng/mL*h) 4997 ± 3187 2160 ± 879 0.029
CL/F (mL/min/kg) 16.1 ± 19.8 47.6 ± 38.2 0.004b
Vd/F (L/kg) 10.3 ± 5.4 9.4 ± 4.2 0.727
UGT2B7*2 non-carriers UGT2B7*2 carriers
Number of patients 10 6
Cmax (ng/mL) 1283 ± 963 956 ± 319 0.444
Tmax (h) 1.8 ± 1.3 1.3 ± 0.7 0.634b
Half-life (h) 6.7 ± 8.0 10.5 ± 8.1 0.369
AUC (ng/mL*h) 3553 ± 3346 3623 ± 1262 0.293b
CL/F (mL/min/kg) 41.0 ± 39.5 16.7 ± 11.6 0.168
Vd/F (L/kg) 10.2 ± 5.1 9.3 ± 4.2 0.728
a
Group differences were evaluated by unpaired t-test or by
b
rank sum test if data were not normally distributed or showed unequal variance.
Cmax, peak concentration; Tmax, time to peak concentration; h, hour; AUC, area under curve; CL/F, apparent oral clearance normalized for body weight;
Vd/F, volume of distribution normalized for body weight.













Kwara et al. Page 20
Table 3
Effect of UGT2B7 allele on mean ± SD zidovudine glucuronidation activity and relative UGT2B7 protein and mRNA
content measured in 52 human liver bank samples.
Parameter UGT2B7*1a non-carriers UGT2B7*1a carriers P valuea
Number of livers 45 7
Zidovudine glucuronidation
(nmoles/min/mg protein) 0.059 ± 0.027 0.054 ± 0.025 0.646
UGT2B7 protein
(relative to lowest) 7.75 ± 2.86 7.25 ± 4.10 0.864b
UGT2B7 mRNA
(relative to lowest) 3.73 ± 2.25 3.56 ± 2.03 0.969b
UGT2B7*1c non-carriers UGT2B7*1c carriers
Number of livers 40 12
Zidovudine glucuronidation
(nmoles/min/mg protein) 0.052 ± 0.022 0.077 ± 0.032 0.020b
UGT2B7 protein
(relative to lowest) 7.14 ± 3.00 9.51 ± 2.32 0.015
UGT2B7 mRNA
(relative to lowest) 3.75 ± 2.03 3.61 ± 2.77 0.863
UGT2B7*2 non-carriers UGT2B7*2 carriers
Number of livers 12 40
Zidovudine glucuronidation
(nmoles/min/mg protein) 0.066 ± 0.032 0.056 ± 0.024 0.238
UGT2B7 protein
(relative to lowest)
8.62 ± 3.73 7.40 ± 2.75 0.160b
UGT2B7 mRNA
(relative to lowest) 2.91 ± 1.63 3.97 ± 2.32 0.188
a
Group differences were evaluated by unpaired t-test or by
b
rank sum test if data were not normally distributed or showed unequal variance.
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